Sino Biopharm (1177.HK) — Upcoming Catalysts
FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Sino Biopharm, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.
For informational purposes only — not investment advice. Track 1177.HK live on Mooboard →
This week1
- Oct 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutD-1553 Tablet · Phase 3 · Non Small Cell Lung CancerNCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure. Primary completion 2026-10 (estimated); status RECRUITING.
31–90 days12
- Nov 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutNTQ5082 capsules 200 mg · Phase 3 · Paroxysmal Nocturnal HemoglobinuriaNCT07177859: A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients. Primary completion 2026-11 (estimated); status NOT_YET_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQH2722 injection · Phase 2 · Seasonal Allergic RhinitisNCT07398859: Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis. Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQB2868 injection · Phase 2 · Pancreatic NeoplasmsNCT06767813: Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms. Primary completion 2026-11 (estimated); status RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutRamelteon · Phase 3 · Chronic InsomniaNCT06512363: A Study of Ramelteon in Chinese Patients With Chronic Insomnia. Primary completion 2026-12 (estimated); status NOT_YET_RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutAK105 Injection · Phase 3 · Advanced Hepatocellular Carcinoma (HCC)NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC). Primary completion 2026-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQC2731 injection · Phase 2 · Chronic Obstructive Pulmonary DiseaseNCT06707883: A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. Primary completion 2026-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQB3454 tablets · Phase 3 · Biliary CarcinomaNCT05987358: A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.. Primary completion 2026-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQB3702 Tablets · Phase 2 · Systemic Lupus ErythematosusNCT06859931: Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE). Primary completion 2026-12 (estimated); status NOT_YET_RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQB3616 capsules, Letrozole, Anastrozole, Tamoxifen · Phase 3 · Breast CancerNCT05780567: Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer. Primary completion 2026-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQB2930 for injection · Phase 1 / Phase 2 · Metastatic Breast Cancer; Recurrent Breast CancerNCT06202261: A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer. Primary completion 2026-12 (estimated); status RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQA2225/AP025 or TQA2225/AP025 Placebo 25mg · Phase 2 · Non-alcoholic SteatohepatitisNCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH). Primary completion 2026-12 (estimated); status RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQ05105 Tablets · Phase 1 / Phase 2 · MyelofibrosisNCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF). Primary completion 2026-12 (estimated); status RECRUITING.
Later12
- Jan 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutAL2846 Capsules · Phase 3 · Thyroid CancerNCT06860971: A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma. Primary completion 2027-01 (estimated); status RECRUITING.
- Jan 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQB2102 for Injection · Phase 3 · Breast CancerNCT06561607: A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer. Primary completion 2027-01 (estimated); status ACTIVE_NOT_RECRUITING.
- Feb 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQC3721 Suspension for Inhalation · Phase 3 · Chronic Obstructive Pulmonary DiseaseNCT07464587: Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Primary completion 2027-02 (estimated); status NOT_YET_RECRUITING.
- Feb 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQB6411 Injection · Phase 1 / Phase 2 · Esophageal CancerNCT07367516: Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer. Primary completion 2027-02 (estimated); status RECRUITING.
- Mar 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQC3721 Suspension for inhalation · Phase 3 · Chronic Obstructive Pulmonary DiseaseNCT07147946: Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Primary completion 2027-03 (estimated); status NOT_YET_RECRUITING.
- Mar 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQB3473 Tablets · Phase 3 · Primary Immune ThrombocytopeniaNCT06900920: A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia. Primary completion 2027-03 (estimated); status RECRUITING.
- Mar 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQC2731 injection · Phase 3 · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07107256: Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps. Primary completion 2027-03 (estimated); status RECRUITING.
- Mar 17, 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQC2938 injection · Phase 2 · Chronic Obstructive Pulmonary DiseaseNCT06789289: A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. Primary completion 2027-03-17 (estimated); status ACTIVE_NOT_RECRUITING.
- Apr 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQB3201 tablets · Phase 1 / Phase 2 · Metastatic Castration-resistant Prostate CancerNCT07172126: Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets. Primary completion 2027-04 (estimated); status NOT_YET_RECRUITING.
- May 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQB2102 for injection · Phase 1 / Phase 2 · Biliary Tract CancerNCT06431490: A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer. Primary completion 2027-05 (estimated); status RECRUITING.
- May 31, 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutNTB003 · Phase 1 / Phase 2 · Thyroid Eye DiseaseNCT07462130: An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED). Primary completion 2027-05-31 (estimated); status NOT_YET_RECRUITING.
- Jun 2027ClinicalTrials.gov ↗Sino Biopharm(1177.HK)Phase 2/3 readoutTQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection · Phase 1 / Phase 2 · Colorectal CancerNCT07653685: A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.. Primary completion 2027-06 (estimated); status RECRUITING.
How Sino Biopharm has moved — past-year price reactions
How binary is 1177.HK? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.
1.4%
1
42%
245
Largest single-day moves
- +12.5%2026-08-20no matched headline
- +8.2%2026-09-21no matched headline
- +8%2026-04-01no matched headline
- -7.5%2025-10-09no matched headline
- +6.9%2026-09-08no matched headline
- -6.6%2026-02-24no matched headline
Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.
Sino Biopharm — active clinical pipeline
Sino Biopharm's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.
94 assets119 programsPh1 31Ph2 47Ph3 36· 5 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyMetabolicNeuroscienceInfectiousRare / GeneticOther
TQB2102 for injectionOncology
TQB2102 InjectionOncology
Phase 1
TQC2731 injectionImmunology
TQB2868 InjectionOncology
Phase 2
TQB3473 TabletsAutoimmune
AK105 InjectionOncology
AL2846 CapsulesOncology
Phase 3
Angiotensin II InjectionOther
Phase 3
Anlotinib hydrochloride capsuleOncology
Phase 3
Anlotinib hydrochloride capsule + TQB2450 injectionOncology
Phase 3
Anlotinib hydrochloride capsules, Penpulimab injectionOncology
Phase 3
D-1553 TabletOncology
Phase 3
LM-302 InjectionOncology
Phase 3
NTQ1062+FulvestrantOncology
NTQ5082 capsules 200 mgRare / Genetic
RamelteonNeuroscience · MTNR1A
Phase 3
Recombinant human activated coagulation factor VIII for injectionRare / Genetic
Phase 3
RovadicitinibImmunology
Phase 3
TQ-B3234 capsulesOther
Phase 3
TQB2450Oncology
Phase 3
TQB2450+AnlotinibOncology
TQB2825 InjectionOncology
Phase 3
TQB2930+ chemotherapyOncology
TQB3616 capsuleOncology
TQB3616 capsules, Letrozole, Anastrozole, TamoxifenOncology
Phase 3
TQB3909 TabletsOther
Phase 3
TQC3721 Suspension for inhalationOther
TQF3510 (Semaglutide Injection)Metabolic
Phase 3
TQH3906 capsulesAutoimmune
Phase 3
TQ05105 tabletsOncology
Phase 1
TQH3906 CapsuleAutoimmune
6.0 mg/kg of TQB2102 for injectionOncology
Phase 2
Benmelstobart injection combined with Anlotinib hydrochloride capsuleOncology
Phase 2
LM-108 injectionOncology
Phase 2
LM-108 injection+Penpulimab+ Oxaliplatin+CapecitabineOncology
Phase 2
NTQ5082 100mg qdRare / Genetic
NTQ5082 capsules 100 mgAutoimmune
Phase 2
Nucleotide drugs Control groupInfectious
Phase 2
TQ05105 TabletImmunology
TQ05105 Tablets (Rovadicitinib Tablets)Oncology
Phase 2
TQA3334 TabletInfectious
Phase 2
TQB2102 for injection (7.5 mg) +Benmelstobart+ChemotherapyOncology
TQB2450 injection + ChemotherapyOncology
Phase 2
TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for InjectionOncology
TQB2825 injection +R-CHOP regimenOncology
TQB2916 InjectionOncology
Phase 2
TQB2916 injection + doxorubicin hydrochloride for injectionOncology
Phase 2
TQB2922 injection ± TAS-102 tabletsOncology
TQB2922 Subcutaneous InjectionOncology
TQB2930 for injectionOncology
Phase 2
TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injectionOncology
Phase 2
TQB2930 injection+TQB2102 for injectionOncology
Phase 2
TQB3126Oncology
Phase 2
TQB3201 tabletsOncology
TQB3616 capsule+Fulvestrant InjectionOncology
Phase 2
TQB3702 TabletsAutoimmune
Phase 2
TQB3702 tablets+Chemotherapy regimenOncology
Phase 2
TQB3909 Tablets + AzacitidineOncology
Phase 2
TQB6411 for InjectionOncology
Phase 2
TQC2938 injectionOther
TQD3524Infectious
TQB2101 for InjectionOncology
TQF3250 capsulesMetabolic
24mg bid TQH3906 capsuleAutoimmune
Phase 1
Anecatibin Fumarate CapsulesOncology
Phase 1
TQ05105Oncology
Phase 1
TQB2029 injectionOncology
Phase 1
TQB2252 injectionOncology
Phase 1
TQB2825 Injection (Subcutaneous Injection)Oncology
TQB2922 for injectionOncology
Phase 1
TQB2922 injection (subcutaneous injection)Oncology
Phase 1
TQB2928 injection + Almonertinib Mesilate TabletsOncology
TQB2934 injection (subcutaneous injection)Oncology
Phase 1
TQB3002 TabletsOncology
Phase 1
TQB3019 capsulesOncology
Phase 1
TQB3107 TabletsOncology
Phase 1
TQB3122 CapsulesOncology
Phase 1
TQB3142 injectionOncology
Phase 1
TQB3205 capsulesOncology
Phase 1
TQB3217TabletsOncology
Phase 1
TQB3455 tablet+Azacitidine for InjectionOncology
Phase 1
TQB3911 tabletsOncology
Phase 1
TQB6426 for InjectionOncology
Phase 1
TQF3250 capsuleOther
Phase 1
TQF6422 InjectionMetabolic
Phase 1
TQH2929 InjectionAutoimmune
Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).
Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built
See the full biopharma catalyst calendar across all covered companies.